Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Long-Term Debt Repayments (2016 - 2018)

Cardiff Oncology's Long-Term Debt Repayments history spans 3 years, with the latest figure at $1.0 million for Q2 2018.

  • For Q2 2018, Long-Term Debt Repayments fell 92.97% year-over-year to $1.0 million; the TTM value through Mar 2019 reached $1.0 million, down 93.04%, while the annual FY2018 figure was $1.2 million, 92.0% down from the prior year.
  • Long-Term Debt Repayments for Q2 2018 was $1.0 million at Cardiff Oncology, up from $156526.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $14.8 million in Q2 2017 and bottomed at -$14.5 million in Q3 2017.
  • The 3-year median for Long-Term Debt Repayments is $538195.0 (2016), against an average of $1.6 million.
  • The largest YoY upside for Long-Term Debt Repayments was 27749.4% in 2017 against a maximum downside of 526.29% in 2017.
  • A 3-year view of Long-Term Debt Repayments shows it stood at $52175.0 in 2016, then surged by 27749.4% to $14.5 million in 2017, then crashed by 92.82% to $1.0 million in 2018.
  • Per Business Quant, the three most recent readings for CRDF's Long-Term Debt Repayments are $1.0 million (Q2 2018), $156526.0 (Q1 2018), and $14.5 million (Q4 2017).